68Ga-PSMA-11 PET/MRI引导活检诊断疑似前列腺癌的前瞻性研究
结果显示PSMA-PET/MRI检测临床显著前列腺癌的患者水平敏感度96%、特异度81%、准确率90%,提示其可作为筛选活检患者的工具。
要点
- PSMA-PET/MRI引导活检检测临床显著前列腺癌准确率达90%。
- 患者水平敏感度96%、特异度81%、阴性预测值93%。
- 9个假阳性病灶中8个经前列腺切除证实为癌。
核心结论
- PSMA-PET/MRI对临床显著前列腺癌具有高检测准确率,是有望用于筛选疑似前列腺癌患者进行活检的工具。
研究设计与样本
- 患者接受PSMA-PET/MRI后行PSMA-PET/MRI引导活检和分区饱和模板活检,以饱和模板活检为参考标准。
主要发现
- 62%的患者发现临床显著前列腺癌(ISUP分级组3和/或癌核心长度≥6 mm)。
- 患者水平敏感度96%、特异度81%、阴性预测值93%、阳性预测值89%、准确率90%。
- 1例患者为PSMA阴性临床显著前列腺癌;9个假阳性病灶中8个经前列腺切除证实为癌,6个假阴性病灶中1个经前列腺切除为阴性。
关键数值与推荐
- 临床显著前列腺癌定义为ISUP分级组3和/或癌核心长度≥6 mm。
- 可疑病灶定义为mpMRI上PIRADS≥3。
临床怎么用
- PSMA-PET/MRI可用于疑似前列腺癌患者的活检前筛选,以减少不必要的活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ultrasound-guided biopsy (US biopsy) with 10-12 cores has a suboptimal sensitivity for clinically significant prostate cancer (sigPCa). If US biopsy is negative, magnetic resonance imaging (MRI)-guided biopsy is recommended, despite a low specificity for lesions with score 3-5 on Prostate Imaging Reporting and Data System (PIRADS). Screening and biopsy guidance using an imaging modality with high accuracy could reduce the number of unnecessary biopsies, reducing side effects. The aim of this study was to assess the performance of positron emission tomography/MRI with 68Ga-labeled prostate-specific membrane antigen (PSMA-PET/MRI) to detect and localize primary sigPCa (ISUP grade group 3 and/or cancer core length ≥ 6 mm) and guide biopsy. METHODS: Prospective, open-label, single-center, non-randomized, diagnostic accuracy study including patients with suspected PCa by elevation of prostate-specific antigen (PSA) level and a suspicious lesion (PIRADS ≥3) on multiparametric MRI (mpMRI). Forty-two patients underwent PSMA-PET/MRI followed by both PSMA-PET/MRI-guided and section-based saturation template biopsy between May 2017 and February 2019. Primary outcome was the accuracy of PSMA-PET/MRI for biopsy guidance using section-based saturation template biopsy as the reference standard. RESULTS: SigPCa was found in 62% of the patients. Patient-based sensitivity, specificity, negative and positive predictive value, and accuracy for sigPCa were 96%, 81%, 93%, 89%, and 90%, respectively. One patient had PSMA-negative sigPCa. Eight of nine false-positive lesions corresponded to cancer on prostatectomy and one in six false-negative lesions was negative on prostatectomy. CONCLUSION: PSMA-PET/MRI has a high accuracy for detecting sigPCa and is a promising tool to select patients with suspicion of PCa for biopsy. TRIAL REGISTRATION: This trial was retrospectively registered under the name "Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men with Elevated PSA" (NCT03187990) on 06/15/2017 ( https://clinicaltrials.gov/ct2/show/NCT03187990 ).
引用
- Ferraro DA, Becker AS, Kranzbühler B, et al. Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. Eur J Nucl Med Mol Imaging. 2021. PMID: 33620559. doi:10.1007/s00259-021-05261-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。